A systematic review involving COVID-19 patients found the prevalence of LA ranging from 35% to 92% in intensive care unit (ICU) patients; aCL IgG and IgM up to 52% and up to 40% of patients, respectively; and aβ2GPI IgG and IgM up to 39% and up to 34% of patients, respectively. This evidence concerns the gene ACLY and COVID-19.